DK175223B1 - Fremgangsmåde til forbedring af produktionen af et önsket polypeptid, DNA-sekvens og rekombinant DNA-molekyle kodende for polypeptidet, værtscelle transformeret med det rekombinante DNA-molekyle og fremgangsmåde til fremstilling af et polypeptid - Google Patents
Fremgangsmåde til forbedring af produktionen af et önsket polypeptid, DNA-sekvens og rekombinant DNA-molekyle kodende for polypeptidet, værtscelle transformeret med det rekombinante DNA-molekyle og fremgangsmåde til fremstilling af et polypeptid Download PDFInfo
- Publication number
- DK175223B1 DK175223B1 DK198605698A DK569886A DK175223B1 DK 175223 B1 DK175223 B1 DK 175223B1 DK 198605698 A DK198605698 A DK 198605698A DK 569886 A DK569886 A DK 569886A DK 175223 B1 DK175223 B1 DK 175223B1
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- smc
- dna
- sequence
- recombinant dna
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 91
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 78
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 76
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 40
- 108020004511 Recombinant DNA Proteins 0.000 title claims description 17
- 102000053602 DNA Human genes 0.000 title claims description 16
- 230000014509 gene expression Effects 0.000 claims abstract description 47
- 230000008569 process Effects 0.000 claims abstract description 11
- 230000002708 enhancing effect Effects 0.000 claims abstract description 3
- 102100021242 Dymeclin Human genes 0.000 claims description 95
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 claims description 95
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 108020004414 DNA Proteins 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 22
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 13
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 241001131785 Escherichia coli HB101 Species 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000000122 growth hormone Substances 0.000 claims description 7
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 4
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 4
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 4
- -1 blood factors Proteins 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 230000002414 glycolytic effect Effects 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 108010074338 Lymphokines Proteins 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 241000187747 Streptomyces Species 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 101710132601 Capsid protein Proteins 0.000 claims description 2
- 101710094648 Coat protein Proteins 0.000 claims description 2
- 102000048120 Galactokinases Human genes 0.000 claims description 2
- 108700023157 Galactokinases Proteins 0.000 claims description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 2
- 101710125418 Major capsid protein Proteins 0.000 claims description 2
- 101710141454 Nucleoprotein Proteins 0.000 claims description 2
- 101710083689 Probable capsid protein Proteins 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229960000182 blood factors Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003677 Sheet moulding compound Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 230000012010 growth Effects 0.000 abstract description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract description 4
- 235000021120 animal protein Nutrition 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 42
- 239000013612 plasmid Substances 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 21
- 239000013598 vector Substances 0.000 description 17
- 230000008878 coupling Effects 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 101150066555 lacZ gene Proteins 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 230000008467 tissue growth Effects 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010076181 Proinsulin Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
- 150000002972 pentoses Chemical class 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 101000633434 Arabidopsis thaliana Structural maintenance of chromosomes protein 1 Proteins 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000006670 Multiple fractures Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 description 2
- 101710117946 Structural maintenance of chromosomes protein 2 Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101710195319 Beta-galactosidase 5 Proteins 0.000 description 1
- 101710122007 Beta-galactosidase BgaB Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000702189 Escherichia virus Mu Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- NEZJDVYDSZTRFS-YBXAARCKSA-N Phenylgalactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1 NEZJDVYDSZTRFS-YBXAARCKSA-N 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100038470 Retinoic acid-induced protein 1 Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000004713 multireference configuration interaction Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 101150054342 ner gene Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 101150106872 rpoH gene Proteins 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 101150023453 smc gene Proteins 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8507833 | 1985-03-26 | ||
| GB858507833A GB8507833D0 (en) | 1985-03-26 | 1985-03-26 | Production of human somatomedin c |
| US8600579 | 1986-03-25 | ||
| PCT/US1986/000579 WO1986005810A1 (en) | 1985-03-26 | 1986-03-25 | Production of human somatomedin c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK569886A DK569886A (da) | 1986-11-26 |
| DK569886D0 DK569886D0 (da) | 1986-11-26 |
| DK175223B1 true DK175223B1 (da) | 2004-07-12 |
Family
ID=10576658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198605698A DK175223B1 (da) | 1985-03-26 | 1986-11-26 | Fremgangsmåde til forbedring af produktionen af et önsket polypeptid, DNA-sekvens og rekombinant DNA-molekyle kodende for polypeptidet, værtscelle transformeret med det rekombinante DNA-molekyle og fremgangsmåde til fremstilling af et polypeptid |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0215110B1 (ja) |
| JP (4) | JPH0691832B2 (ja) |
| CN (1) | CN1034588C (ja) |
| AT (1) | ATE87977T1 (ja) |
| AU (1) | AU594950B2 (ja) |
| CA (1) | CA1339305C (ja) |
| DE (1) | DE3688225T2 (ja) |
| DK (1) | DK175223B1 (ja) |
| ES (1) | ES8705921A1 (ja) |
| GB (1) | GB8507833D0 (ja) |
| IL (1) | IL78278A0 (ja) |
| NO (1) | NO302709B1 (ja) |
| WO (1) | WO1986005810A1 (ja) |
| ZA (1) | ZA862240B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0260149A1 (en) * | 1986-09-12 | 1988-03-16 | Howard Florey Institute Of Experimental Physiology And Medicine | Human prorelaxin for therapeutic use |
| GB8712540D0 (en) * | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US4876242A (en) * | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
| AUPP807899A0 (en) | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
| JP6018719B1 (ja) * | 2016-03-15 | 2016-11-02 | Ｂｘ新生精機株式会社 | シャッター開閉機の巻上装置 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE95236T1 (de) * | 1983-04-25 | 1993-10-15 | Chiron Corp | Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren. |
| IL71991A (en) * | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| SE8303626D0 (sv) * | 1983-06-23 | 1983-06-23 | Kabigen Ab | A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced |
| EP0151760A1 (en) * | 1984-01-06 | 1985-08-21 | Takeda Chemical Industries, Ltd. | Novel DNA and use thereof |
| US4758512A (en) * | 1984-03-06 | 1988-07-19 | President And Fellows Of Harvard College | Hosts and methods for producing recombinant products in high yields |
-
1985
- 1985-03-26 GB GB858507833A patent/GB8507833D0/en active Pending
-
1986
- 1986-03-21 CA CA000504757A patent/CA1339305C/en not_active Expired - Lifetime
- 1986-03-25 ES ES553374A patent/ES8705921A1/es not_active Expired
- 1986-03-25 ZA ZA862240A patent/ZA862240B/xx unknown
- 1986-03-25 WO PCT/US1986/000579 patent/WO1986005810A1/en active IP Right Grant
- 1986-03-25 JP JP61501992A patent/JPH0691832B2/ja not_active Expired - Lifetime
- 1986-03-25 AT AT86902217T patent/ATE87977T1/de not_active IP Right Cessation
- 1986-03-25 DE DE8686902217T patent/DE3688225T2/de not_active Expired - Lifetime
- 1986-03-25 AU AU56657/86A patent/AU594950B2/en not_active Expired
- 1986-03-25 EP EP86902217A patent/EP0215110B1/en not_active Expired - Lifetime
- 1986-03-26 IL IL78278A patent/IL78278A0/xx unknown
- 1986-03-26 CN CN86102889A patent/CN1034588C/zh not_active Expired - Lifetime
- 1986-11-25 NO NO864724A patent/NO302709B1/no unknown
- 1986-11-26 DK DK198605698A patent/DK175223B1/da not_active IP Right Cessation
-
1994
- 1994-05-09 JP JP6117443A patent/JP2602628B2/ja not_active Expired - Lifetime
- 1994-05-09 JP JP6117430A patent/JP2568383B2/ja not_active Expired - Lifetime
- 1994-05-09 JP JP6117435A patent/JPH07102152B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0215110A4 (en) | 1987-07-09 |
| GB8507833D0 (en) | 1985-05-01 |
| DE3688225T2 (de) | 1993-07-22 |
| ES553374A0 (es) | 1987-05-16 |
| NO864724L (no) | 1987-01-23 |
| NO302709B1 (no) | 1998-04-14 |
| JPS62502305A (ja) | 1987-09-10 |
| JPH07145200A (ja) | 1995-06-06 |
| JPH07102152B2 (ja) | 1995-11-08 |
| AU5665786A (en) | 1986-10-23 |
| ZA862240B (en) | 1986-11-26 |
| EP0215110B1 (en) | 1993-04-07 |
| ATE87977T1 (de) | 1993-04-15 |
| DE3688225D1 (de) | 1993-05-13 |
| JP2602628B2 (ja) | 1997-04-23 |
| CN86102889A (zh) | 1986-11-26 |
| WO1986005810A1 (en) | 1986-10-09 |
| DK569886A (da) | 1986-11-26 |
| DK569886D0 (da) | 1986-11-26 |
| EP0215110A1 (en) | 1987-03-25 |
| ES8705921A1 (es) | 1987-05-16 |
| JP2568383B2 (ja) | 1997-01-08 |
| AU594950B2 (en) | 1990-03-22 |
| JPH07143885A (ja) | 1995-06-06 |
| CA1339305C (en) | 1997-08-19 |
| JPH07143896A (ja) | 1995-06-06 |
| IL78278A0 (en) | 1986-07-31 |
| JPH0691832B2 (ja) | 1994-11-16 |
| CN1034588C (zh) | 1997-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO832948L (no) | Veksthormon | |
| AU620673B2 (en) | Somatotropin analogs | |
| DK175217B1 (da) | Hirudinanalog, vektorer til ekspression af hirudinanalog, transformerede celler og fremgangsmåde til fremstilling af hirudinanalog | |
| US5304473A (en) | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production | |
| Van Eldik et al. | Synthesis and expression of a gene coding for the calcium-modulated protein S100 beta and designed for cassette-based, site-directed mutagenesis. | |
| EP0200986B1 (en) | Recombinant human interleukin-1 | |
| NO179253B (no) | Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet | |
| CZ284204B6 (cs) | Zvyšování sekrece polypeptidů | |
| EP0488479A1 (en) | DNA sequences, recombinant DNA molecules and processes for producing swine growth hormone-like polypeptides | |
| EP0618227A1 (en) | Biologically active polypeptide fusion dimers | |
| JP4280786B2 (ja) | 同一のｎ末端を有する塩基性繊維芽細胞増殖因子の高レベル発現 | |
| DK175223B1 (da) | Fremgangsmåde til forbedring af produktionen af et önsket polypeptid, DNA-sekvens og rekombinant DNA-molekyle kodende for polypeptidet, værtscelle transformeret med det rekombinante DNA-molekyle og fremgangsmåde til fremstilling af et polypeptid | |
| EP0070675A1 (en) | Human calcitonin precursor polyprotein structural gene | |
| Sumi et al. | Overproduction of human epidermal growth factor/urogastrone in Escherichia coli and demonstration of its full biological activities | |
| EP0496973B1 (en) | Porcine somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations | |
| EP0153961B1 (en) | Recombinant materials and methods for producing human connective tissue-activating peptide-iii and analogs thereof | |
| US5654177A (en) | Production of human somatomedin C | |
| Fujimoto et al. | Expression and secretion of human epidermal growth factor by Escherichia coli using enterotoxin signal sequences | |
| NZ231443A (en) | Improved production of a specific polypeptide in a transformed host |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |